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From the Editor’s Desk
TILTING AT TITLES
The call “Is there a doctor on board?” is 
unambiguous. There may be doctors of 
philosophy, science or literature “on 
board”, but there is no confusion as to 
what sort of doctor is needed.  
In the United Kingdom, and less so in 
Australia, medicine’s titles include 
Doctor, Mister and Miss. The 
appellation, Mister (Master), follows a 
tradition reaching back to the 16th 
century, when Henry VIII granted a royal 
charter to the Company of Barber-
Surgeons. The demarcation was clear — 
physicians were university graduates 
and surgeons were apprentices of 
Barber-Surgeons. 
Two centuries later, surgeons split 
from the Company, but clung to their 
distinctive title. Now it seems that the 
days of Mister or Miss are numbered.
With the increasing involvement of 
non-medically qualified professionals 
(many with PhDs) in health care, 
patients are confused about who, of the 
Doctor, Mister or Miss, is actually their 
doctor. The late Hugh Phillips, past 
president of the Royal College of 
Surgeons of England, labelled the use of 
Mister as old tribalism and 
anachronistic. He argued for surgeons to 
return to the title of Doctor, noting: 
“There has been concern recently about 
who people are in the health service — 
who is actually treating you? It is not 
always absolutely clear to the patient, I 
suspect, and it is not even clear as to 
whether someone is a doctor.” Whether 
UK surgeons will heed this advice has 
yet to be resolved.
In Australia, surgeons who persist in 
using Mister are in the minority. But 
given Australia’s egalitarianism and low 
tolerance of titles, should we not trash 
titles altogether? Should we not stress 
expertise and competence, and move to: 
“Hello. I’m Jean Smith. I am a urologist 
and together we will confront your 
prostate problem”? This would put 
patients firmly in the picture.
Martin B Van Der Weyden
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Letters
Early medical abortion in 
Australia: more common than 
statistics suggest?
Caroline M de Costa
TO THE EDITOR: Since my article on
medical abortion was published in the Jour-
nal,1 I have received some information from
colleagues, and from women who have
undergone abortions, about the current
practice of medical abortion in Australia. I
believe this may be of interest to readers of
the MJA.
More than a dozen practitioners have
informed me that they have used misopros-
tol or methotrexate/misoprostol combina-
tions to induce early abortion (before 9
weeks’ gestation) outside of hospitals, and a
number of women have reported undergo-
ing such abortions. The number of cases
involved in this anecdotal sample is at least
several hundred annually.
Induced abortion using methotrexate/
misoprostol was practised in the United
States up until the introduction there of
mifepristone/misoprostol regimens in
2000.2,3 There is wide experience of this
drug combination reported in the medical
literature, and the consensus is that, in the
short term at least, it is safe and effective,
although less effective than the mifepristone/
misoprostol combination.2-4 Both drugs are
licensed for purposes other than abortion in
Australia, as elsewhere (misoprostol for
treatment of gastric ulceration; methotrexate
as a cytotoxic agent, and for psoriasis and
rheumatoid arthritis), but the use of drugs
“off-label” is an acknowledged medical prac-
tice.5 Misoprostol in particular is widely
used in obstetrics for cervical ripening and
treatment of postpartum haemorrhage.5
These early abortions take place “under
the radar” in the sense that there is no
specific Medicare item number; the admin-
istration of the drugs occurs in the course of
a standard consultation. There is nothing
irregular about this, but it does mean that
the inaccurate data we currently have on the
number of abortions performed in Australia
are even more inaccurate than initially
thought. It should be noted also that miso-
prostol alone or in combination with other
prostaglandins is being used in Australian
hospitals, as overseas, in a more evident
manner for the induction of late abortion in
cases of severe fetal abnormality detected
after 13 weeks’ gestation.5 As well, meth-
otrexate is commonly used in the treatment
of early, unruptured ectopic pregnancy, in
doses well below those used in oncology.
The communications I have received on
the subject lead me to believe that medical
abortion is currently extensively practised in
Australia.
Caroline M de Costa, Professor of Obstetrics 
and Gynaecology
James Cook University School of Medicine, 
Cairns Campus, Cairns, QLD.
caroline.decosta@jcu.edu.au
1 de Costa CM. Medical abortion for Australian
women: it’s time. Med J Aust 2005; 183: 378-380. 
2 Creinin MD, Potter C, Holovanisin M, et al. Mifepris-
tone and misoprostol and methotrexate/misopros-
tol in clinical practice for abortion. Am J Obstet
Gynecol 2003; 188: 664-669.
3 Pymar HC, Creinin MD. Alternatives to mifepristone
regimens for medical abortion. Am J Obstet Gyne-
col 2000; 183 (2 Suppl): S54-S64.
4 Say L, Kulier R, Gulmezoglu M, Campana A. Medi-
cal versus surgical methods for first trimester termi-
nation of pregnancy. Cochrane Database Syst Rev
2005; (1): CD003037.
5 Chong YS, Su LL, Arulkumaran S. Misoprostol: a
quarter century of use, abuse and creative misuse.
Obstet Gynecol Surv 2004; 59: 128-140. ❏
A champion-driven pathway 
towards quality improvement 
in the medical management of 
osteoporotic fractures
Tim Yu-Ting Lu, Jennifer A Pink, 
Lauren E Whitten, Catherine L Hill, 
Robert J Adams and Catherine Gibb
TO THE EDITOR: The Australian Fracture
Prevention Summit held in 2002 recognised
osteoporosis as a major public health issue.
Despite this, several Australian studies have
found that a majority of patients with oste-
oporosis-related fractures do not receive
appropriate evaluation and treatment as rec-
ommended by the clinical guidelines.1-4
In 2003, the Queen Elizabeth Hospital, a
tertiary referral hospital which services the
north-western suburbs of metropolitan
Adelaide, implemented a novel approach to
improve the secondary prevention manage-
ment of patients admitted to the orthopae-
dic unit with fragility fractures. The strategy
was based on the “plan-do-study-action”
principle of medical quality improvement,
with the primary goal of enhancing perform-
ance.5
Before commencing, a retrospective case-
note review of 40 consecutive patients who
had been admitted to the orthopaedic unit
with osteoporotic fractures revealed that, at
discharge, none were receiving any medica-
tion for osteoporosis.
Patients over the age of 50 years who had
been admitted with fragility fractures were
identified from computer records. With the
support of a physician and junior medical
staff, a clinical pharmacist provided indi-
vidual counselling, written materials and
osteoporosis therapy. The rate of medica-
tion prescription was initially assessed at
discharge. In a follow-up telephone inter-
view, participants were queried about the
continuation of osteoporosis therapy, per-
formance of investigations by general prac-
titioners, and history of falls.
Over a 10-month period, of 259 patients
admitted with fragility fractures, 228
patients (88%) were prescribed osteoporo-
sis therapy (calcium, vitamin D and risedr-
onate) on discharge. Of those eligible, 65
patients participated in the follow-up
audit. Forty-eight patients (74%) contin-
ued to take medications for osteoporosis as
initially prescribed; only 28% had had
laboratory investigations for osteoporosis
and 31% a bone mineral density test. In
addition, three patients had experienced
recurrent falls complicated by further fra-
gility fractures.
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LETTERSThe appointment of an allied health
champion with clinical backup from a gen-
eral physician appeared to have achieved a
high level of initiation and continuation of
osteoporosis pharmacotherapy in at-risk
patients during hospital admission. The low
rate of follow-up investigations is consistent
with previously published data suggesting
poor community-based follow-up after hos-
pital discharge of patients admitted for
osteoporotic fractures.
The major limitation of this clinical path-
way is the low rate of patient participation in
the follow-up audit. Therefore, the results of
follow-up data cannot be said to be repre-
sentative of the cohort.
This study highlights the importance of
the participation of GPs in maintaining
patient compliance with hospital-initiated
programs, especially those involving chronic
illnesses.
Acknowledgements: We would like to thank Mr C
Butcher, Head of the Orthopaedic Unit at the
Queen Elizabeth Hospital, for his ongoing support
of this program. We are grateful for the medication
provided by Aventis Pharma.
Competing interests: Aventis Pharma provided
risedronate for the research.
Tim Yu-Ting Lu, Rheumatology Registrar
Jennifer A Pink, Specialist Pharmacist
Lauren E Whitten, Clinical Pharmacist
Catherine L Hill, Rheumatologist
Robert J Adams, Associate Professor of 
Medicine
Catherine Gibb, Physician
Queen Elizabeth Hospital, Adelaide, SA.
mugzy@ozemail.com.au
1 Feldstein AC, Nichols GA, Elmer PJ, et al. Older
women with fractures: patients falling through the
cracks of guideline-recommended osteoporosis
screening and treatment. J Bone Joint Surg Am
2003; 85-A: 2294-2302.
2 Freedman KB, Kaplan FS, Bilker WB, et al. Treat-
ment of osteoporosis: are physicians missing an
opportunity? J Bone Joint Surg Am 2000; 82-A:
1063-1070.
3 Harrington JT, Broy SB, Derosa AM, et al. Hip
fracture patients are not treated for osteoporosis: a
call to action. Arthritis Rheum 2002; 47: 651-654.
4 Kamel HK, Hussain MS, Tariq A, et al. Failure to
diagnose and treat osteoporosis in elderly patients
hospitalized with hip fracture. Am J Med 2000; 109:
326-328.
5 Davidoff F, Batalden P. Toward stronger evidence
on quality improvement. Draft publication guide-
lines: the beginning of a consensus project. Qual
Saf Health Care 2005; 14: 319-325. ❏
Clinical trials of unapproved 
medicines in Australia
Jonathon Rankin, Jenny Mason, 
Neil Kottege and Natasha Y Andersson
TO THE EDITOR: The Experimental
Drugs Section (EDS) of the Drug Safety
and Evaluation Branch of the Therapeutic
Goods Administration (TGA) administers
the clinical trial notification (CTN) and
clinical trial exemption (CTX) arrange-
ments for unapproved medicines used in
clinical trials. These arrangements provide
an avenue of “exemption”, whereby medi-
cines that have not been approved for
marketing in Australia are able to be
supplied to patients within the context of
a clinical trial approved by a human
research ethics committee working under
the guidelines of the Australian Health
Ethics Committee (a subcommittee of the
National Health and Medical Research
Council). Although these arrangements
cover only clinical trials in which unap-
proved medicines are used, a substantial
number of such trials are carried out in
Australia each year. (Clinical trials using
unapproved medical devices that also use
the CTN/CTX arrangements are adminis-
tered by the TGA’s Office of Blood, Devices
and Tissues and are not included in these
statistics.)
The EDS often receives queries from
stakeholders requesting some form of basic
statistical data with respect to clinical trial
activity in Australia. The EDS intends to
begin use of a new database in 2007 for
recording CTNs and CTXs notified to the
TGA. It is hoped that this will enable us to
publish a basic statistical subset of clinical
trial information on an annual basis. As a
prelude to this capability, we have manu-
ally compiled a few simple statistics on
clinical trials notified within the financial
year 2004–05.
Box 1 breaks down the trials conducted
into various body systems or treatment
areas. There were 739 separate clinical
trials of unapproved medicines com-
menced over the 1-year period. As many of
these are multicentre trials, there are a
much greater number of actual trial sites
involved. (A good measure of the number
of trial sites is simply the raw CTN notifica-
tion figures, numbering 2776 for the same
period.)
Box 2 breaks down the trial numbers
into the various phases of drug develop-
ment. Although this is not relevant to all
trials, these figures give an indication of the
main areas of drug development research
currently being conducted in Australia.
Given the number of multicentre trials
being carried out, we did not think it useful
to break down trial numbers by state and
territory. We trust that these data convey
1 Clinical trials of unapproved 
medicines, by body system and 







Central nervous system 71
Immunology 64
Endocrine and metabolic 
disorders
60













* Based on clinical trial notification and clinical trial 
exemption data. † “Unspecified” refers either to 
trials that were not directed toward a body system 
or trials in which the system could not be 
determined from the information on the clinical 
trial notification form. ◆
2 Clinical trials of unapproved 
medicines, by trial phase, July 
2004 to June 2005*
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LETTERSsome idea of current clinical trial activity
with respect to unapproved medicines in
Australia.
Jonathon Rankin, Head of Unit
Jenny Mason, Senior Professional Officer
Neil Kottege, Professional Officer
Natasha Y Andersson, Clinical Trial Officer
Experimental Drugs Section, Drug Safety
and Evaluation Branch, Therapeutic Goods 
Administration, Australian Government 
Department of Health and Ageing, 
Canberra, ACT.
jon.rankin@health.gov.au ❏
The repeating history of 
objections to the fortification 
of bread and alcohol: from iron 
filings to folic acid
Hasantha Gunasekera
The recent viewpoint by Kamien1 is timely,
given Food Standards Australia New Zea-
land is currently advocating for the manda-
tory fortification of all bread-making flour
with folic acid (80–180μg per 100g of
bread). The proposal is now before the
Australia and New Zealand Food Regula-
tion Ministerial Council, and a decision is
imminent.
In 1991, the Medical Research Council
Vitamin Study Research Group reported a
randomised double-blind trial conducted
at 33 centres in seven countries. Pericon-
ceptual folic acid supplementation had a
72% protective effect against neural tube
defects (relative risk, 0.28; 95% CI, 0.12–
0.71).2 Because folic acid supplementation
is ineffective when started after the preg-
nancy is confirmed, fortification of staple
foods such as bread remains best practice.
The United States started mandatory for-
tification of enriched cereal-grain products
a decade ago. As expected, there has been
an increase in the population geometric
mean concentrations of serum folate and
red blood cell folate,3 and a corresponding
reduction in the number of babies born
with debilitating neural tube defects.4
The benefits are clear and the risks are
vague. Historical concerns that folic acid
supplementation could mask pernicious
anaemia and cause cancer have not been
substantiated by international experience
in more than 50 countries.
Australian health professionals have a
brief window of opportunity to join Mab-
erly and Stanley5 and advocate for manda-
tory fortification in spite of commercial
objections, which are based on market-
share concerns for existing “designer”
products. If we educate and inform our
patients and the community at large, the
decisionmakers should finally get the mes-
sage and this cheap, safe and effective
public health policy would be imple-
mented — a decade overdue.
Hasantha Gunasekera, Clinical Research Fellow
Institute for Child Health Research, The 
Children’s Hospital at Westmead, Sydney, NSW.
hasanthg@chw.edu.auMJA • Volume 185 Number 6 • 18 September 2006 343
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Weight management in 
general practice: 
what do patients want?
Claire Hewat
TO THE EDITOR: Tan et al1 found that
patients value key elements of successful
weight management, including advice on
healthy eating and exercise and regular
follow-up. Accredited practising dietitians
(APDs) provide all of these things and have
the qualifications, skills and time to work
with people to effectively manage weight.
APDs use the Obesity Best Practice Guide-
lines of the Dietitians Association of Aus-
tralia, providing evidence-based dietary
therapy.
By working alongside general practitioners
to provide individual advice, APDs ensure the
best outcomes for patients. A considerable
number of patients surveyed said that referral
to a dietitian would be useful and that they
would be likely to follow their GP’s advice if
referral was recommended.
The weight management roles of GPs and
APDs are complementary and, by addressing
any patient concerns and providing a referral
to an APD, GPs can help their patients
achieve their weight management goals.
Claire Hewat, Executive Director
Dietitians Association of Australia, Canberra, ACT.
taniaf@adam.com.au
6 Tan D, Zwar NA, Dennis SM, Vagholkar S. Weight
management in general practice: what do patients
want? Med J Aust 2006; 185: 73-75. ❏
Editor
Martin Van Der Weyden, MD, FRACP, FRCPA
Deputy Editors
Bronwyn Gaut, MBBS, DCH, DA
Ruth Armstrong, BMed
Ann Gregory, MBBS, GradCertPopHealth
Tanya Grassi, MBBS(Hons), BSc(Vet)(Hons)
Manager, Communications Development
Craig Bingham, BA(Hons), DipEd
Senior Assistant Editor
Helen Randall, BSc, DipOT
Assistant Editors
Elsina Meyer, BSc
Kerrie Lawson, BSc(Hons), PhD, MASM
Tim Badgery-Parker, BSc(Hons), ELS
Josephine Wall, BA, BAppSci, GradDipLib
Scientific Proof Readers
Christine Binskin, BSc; Sara Thomas, BSc; 














Val Gebski, BA, MStat
Content Review Committee
Craig S Anderson, PhD, FRACP;
Leon A Bach, PhD, FRACP;
Flavia M Cicuttini, PhD, FRACP;
Jennifer J Conn, FRACP, MClinEd;
Marie-Louise B Dick, MPH, FRACGP;
Mark F Harris, MD, FRACGP;
Paul D R Johnson, PhD, FRACP;
Tom Kotsimbos, MD, FRACP;
Campbell Thompson, MD, FRACP;
Tim P Usherwood, MD, FRCGP;
E Haydn Walters, DM, FRACP;
Owen D Williamson, FRACS, GradDipClinEpi;
Jane Young, PhD, FAFPHM;
Jeffrey D Zajac, PhD, FRACP 
Australasian Medical Publishing Co Pty Ltd
Advertising Manager: Peter Butterfield
Media Coordinators: Kendall Byron; Julie Chappell
The Medical Journal of Australia (MJA) is published on the 1st 
and 3rd Monday of each month by the Australasian Medical 
Publishing Company Proprietary Limited, Level 2, 26-32 
Pyrmont Bridge Rd, Pyrmont, NSW 2009. ABN 20 000 005 854. 
Telephone: (02) 9562 6666. Fax: (02) 9562 6699. 
E-mail: medjaust@ampco.com.au. The Journal is printed by 
Offset Alpine Printing Ltd, 42 Boorea St, Lidcombe, NSW 2141.
MJA on the Internet: http://www.mja.com.au/
None of the Australasian Medical Publishing Company 
Proprietary Limited, ABN 20 000 005 854, the Australian 
Medical Association Limited, or any of its servants and agents 
will have any liability in any way arising from information or 
advice that is contained in The Medical Journal of Australia 
(MJA). The statements or opinions that are expressed in the 
Journal reflect the views of the authors and do not represent 
the official policy of the Australian Medical Association unless 
this is so stated. Although all accepted advertising material 
is expected to conform to ethical and legal standards, such 
acceptance does not imply endorsement by the Journal.
All literary matter in the Journal is covered by copyright, and 
must not be reproduced, stored in a retrieval system, or 
transmitted in any form by electronic or mechanical means, 
photocopying, or recording, without written permission.
Published in 2 volumes per year. 
Annual Subscription Rates for 2007 (Payable in Advance) to: 
AMPCo, Locked Bag 3030, Strawberry Hills, NSW 2012
Individual Subscriptions (includes 10% GST) 
Australia: $A368.50, Medical students (Australia only): $A60.00
Overseas: $A474.00
Indexes are published every 6 months and are available on 
request as part of the current subscription.
Single or back issues contact: AMPCo (02) 9562 6666.
Advice to Authors—
http://www.mja.com.au/public/information/instruc.html
27,649 circulation as at
24 April, 2006 ISSN 0025-729X
— eMJA
Most popular articles from 
3/17 July issues




Physician assistants and nurse 




Re-inventing medical work and 
training: a view from generation X.
www.mja.com.au/public/issues/185_01_030706/
ski10329_fm.html








Patients presenting to the general 




Principles for supporting task 




When the tide goes out: health 




Weight management in general 
practice: what do patients want? 
www.mja.com.au/public/issues/185_02_170706/
tan10063_fm.html
Task transfer: the view of the Royal 
Australasian College of Physicians.
www.mja.com.au/public/issues/185_01_030706/
sew10531_fm.html344 MJA • Volume 185 Number 6 • 18 September 2006
